4 assets in SMARCA4-Deficient Sarcoma Of Thorax

Therapeutic assets addressing SMARCA4-Deficient Sarcoma Of Thorax, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin SMARCA4-Deficient Sarcoma Of Thorax	Zhijie Wang	P2	B (60)
Cis-Diamminedichloroplatinum Ii SMARCA4-Deficient Sarcoma Of Thorax	Eli Lilly and Company	P1	CC (43)
ly4050784 SMARCA4-Deficient Sarcoma Of Thorax	Eli Lilly and Company	P1	CC (43)
Pembrolizumab SMARCA4-Deficient Sarcoma Of Thorax	Eli Lilly and Company	P1	CC (43)